Dr. El Hadji Seydou Mbaye was born in 1978 in Kaolack a region of Senegal. During 2008-2013, he earned his PhD in Biology and Human Pathologies with the collaboration of the International Agency for Research on Cancer / World Health Organization, (IARC/WHO), Lyon (France); He obtained a Master’s of Life and Health, Specialty Biology of microorganisms, Virology; a Master’s of Life and Health, option Immuno-physiopathology; a License of Biochemistry in Louis Pasteur University of Strasbourg (France); and a General Degree in Sciences and Technologies in University of METZ (France). He was certified Grade 10/10 by the Federation International of Gynecology Obstetric (FIGO), the Accreditation Council of Oncology in Europe (ACOE), and the Institute Catalan of Oncology (ICO). These credits were recognized as Physician’s Recognition Award (AMA PRA Category 1) by the American Medical Association.He was awarded asInternational Outstanding Scientist Awards 2020, Awarded as the Best Researcher Award 2021, by VDGOOD. He was certified, by the United Nations, byIARC/WHO. He has published 1 Book with a style of philosophical story. Author of the World Program against Cancer in Low and Middle Incomes Countries, he is lead author of more than 90 peer-reviewed research articles published in reputed journals. Dr. Mbaye is Editor-in-Chief of 4 journals, Editorial Board Member of 157 International Journals, and then he has Edited/Reviewed 270 peer-reviewed articles. He is member of Allied Academies, member of the World Society for Virology (WSV),member of World’s Leading Virologists Group: Facing to Covid-19, member of U.S. National Academies of Sciences, Engineering, and Medicine (NASEM): Societal Experts Action Network (SEAN), and also, member of BCNet International Working Group, IARC/WHO.Dr. MBAYE has formed for free, more than 250 Healthcare Professionals for the techniques of cervical cancer screening in Senegal. He has screened for free more than 2000 women for cervical cancer in Senegal. He appeared on local media, 2S TV, Leeral.net, Mbour TV, Sen TV and 7TV.

Associate Professor Dr. Thomas Böldicke is senior scientist at the Helmholtz Centre for Infection Research (HZI, former GBF) and project leader Cancer Immunotherapy. He developed recombinant antibodies against tumor antigens, particularly against tumor angiogenesis, rhabdyomyosarcoma and recently against TLR2 and TLR9 in pancreatic cancer. He has a collaboration with Prof. Waaga Gasser in Harvard, Medical School about adaptive T-cell therapies. Over 10 years he gave lectures at the Technical University in Braunschweig about immunology, cancer development and immunotherapies. He is in the editorial board of the journal Antibodies as academic editor and co-editor and academic editor in Frontiers in Immunology.